All In Biotech

Drug Trial Radar · NCT00622349

Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer

A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens in Patients With Non Pre-treated Advanced Non-small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jan 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 707 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

707

Actual

Start

Feb 2004

Primary completion

Mar 2009

Study completion Dec 2009

Sponsor

Lead sponsor
European Lung Cancer Working PartyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if cisplatin-based chemotherapy, cisplatin-gemcitabine-ifosfamide or cisplatin-docetaxel, will improve survival in comparison to the combination gemcitabine-ifosfamide in patients with advanced NSCLC

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • Cisplatin, Ifosfamide, GemcitabineDrug

    Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks

  • Ifosfamide, GemcitabineDrug

    Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks

  • Cisplatin, docetaxelDrug

    Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SurvivalTime frame: Survival will be dated from the first day of registration until death or last follow up

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet

    Brussels, Belgium

  • Pneumology department of CHU Lille

    Lille, France

  • Hellenic Cancer Institute - St Savas Oncology Hospital

    Athens, Greece

  • Medical Oncology Hospital de Sagunto

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.